ERIS.NS Cash Flow
Eris Lifesciences Ltd.
Profit & Loss Balance Sheet Cash Flow
Cash Flow · 4 years on file
(FY2022-23 to FY2025-26)
· fetched 2026-08-24 01:34
| Line item | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|
| Net Cash from Operating Activities | ₹291.74 Cr. | ₹486.01 Cr. | ₹1,065.01 Cr. | ₹537.99 Cr. | CashFlowsFromUsedInOperatingActivities |
| Net Cash from Investing Activities | ₹-974.61 Cr. | ₹-1,827.56 Cr. | ₹-79.97 Cr. | ₹-369.46 Cr. | CashFlowsFromUsedInInvestingActivities |
| Net Cash from Financing Activities | ₹688.02 Cr. | ₹1,379.78 Cr. | ₹-881.32 Cr. | ₹-313.53 Cr. | CashFlowsFromUsedInFinancingActivities |
| Effect of Exchange Rate Changes | ₹0.00 Cr. | ₹0.00 Cr. | ₹0.00 Cr. | ₹0.00 Cr. | EffectOfExchangeRateChangesOnCashAndCashEquivalents |
| Net Increase/(Decrease) in Cash | ₹5.15 Cr. | ₹38.22 Cr. | ₹103.72 Cr. | ₹-145.00 Cr. | IncreaseDecreaseInCashAndCashEquivalents |
| Cash and Cash Equivalents (Closing) | ₹50.87 Cr. | ₹56.02 Cr. | N/A | N/A | CashAndCashEquivalentsCashFlowStatement |
Every figure above is the exact value of the named XBRL element from ERIS.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).